Sumitomo Mitsui DS资产管理公司将其在Edwards Lifesciences Co.的股份减少了38.5%。 Sumitomo Mitsui DS Asset Management reduced its stake in Edwards Lifesciences Co. by 38.5%.

Sumitomo Mitsui DS资产管理公司在Edwards Livesciences Co.(NYSE:EW)的股份减少了38.5%,在出售49 382股后持有78 949股。 Sumitomo Mitsui DS Asset Management reduced its stake in Edwards Lifesciences Co. (NYSE:EW) by 38.5%, holding 78,949 shares after selling 49,382. 机构投资者拥有公司79.46%的股份。 Institutional investors own 79.46% of the company. Edwards报告Q2收入为每股0.70美元,超过估计, Edwards reported Q2 earnings of $0.70 per share, surpassing estimates, and has a "Hold" rating with a target price of $75.81. 芝加哥资本有限公司在爱德华兹和利根德制药公司也担任重要职务。 Chicago Capital LLC also holds significant positions in Edwards and Ligand Pharmaceuticals.